Frequently Asked Questions


FAQs

To begin your FMC journey, simply complete our quick online medical intake form. Your responses are private and reviewed by our clinical team. During your first telehealth visit, your provider will confirm your eligibility and recommend the GLP-1 medication that best aligns with your weight-loss goals. One form. One appointment. A completely personalized treatment plan.

Tirzepatide and Semaglutide are FDA-approved active ingredients used in Mounjaro®, Zepbound®, Ozempic®, and Wegovy®, which have helped millions of people lose and maintain weight.


Medically approved patients are typically prescribed Tirzepatide or Semaglutide injections, which are slowly absorbed by the body over a week’s duration to help curb appetite and reduce cravings.


The Tirzepatide or Semaglutide GLP-1 medication you may be prescribed is a compounded generic medication and is not associated with the pharmaceutical companies Eli Lilly™ or Novo Nordisk™, nor their brand-name medications Mounjaro®, Zepbound®, Ozempic®, or Wegovy®.

Mounjaro® & Zepbound® (Tirzepatide) work differently than other drugs in the GLP-1 family, as they contain an extra molecule that may give them a slight edge. These medications mimic two incretin hormones (GLP-1 and GIP), affecting appetite and satiety.


Ozempic® & Wegovy® (Semaglutide) regulate food intake and appetite by acting as human GLP-1 receptor agonists. They suppress appetite, control cravings, and help you feel full longer by slowing stomach emptying.


When combined with diet and exercise, GLP-1 medications can lead to significant weight loss and reduce risks of diabetes, cancer, and heart disease in overweight individuals.

Yes. Your medical data and order history are viewable only by our medical team. You can review our Privacy Policy for more information.

If you are eligible for treatment, our medical team will issue a prescription for either Tirzepatide (the active ingredient in Mounjaro® & Zepbound®) or Semaglutide (the active ingredient in Ozempic® & Wegovy®). You do not need an existing prescription to join the FMC weight-loss program.

Our program is not eligible for coverage through health-insurance providers. Participants pay directly via ACH transfer, credit, or debit card — ensuring flexible and convenient access to their health journey.

Our subscription plans vary based on duration and provide significant savings compared to retail prices — Mounjaro®, Zepbound®, Ozempic®, and Wegovy® average $1,300–$1,500 per month. FMC offers the same active ingredients for a fraction of the cost while including consultations, prescriptions, and shipping.


For complete pricing on our subscription weight-loss plans, CLICK HERE.

Yes. The telehealth consultation, prescription, GLP-1 medication, and shipment are all included in your subscription — no hidden fees.

Your shipment will arrive promptly after our clinicians review your monthly progress and issue the next prescription, ensuring you always have medication on hand to continue your journey.

A monthly follow-up telehealth appointment is required to discuss your progress with your clinician. They’ll adjust your GLP-1 medication — Semaglutide (Ozempic®, Wegovy®) or Tirzepatide (Mounjaro®, Zepbound®) — as needed to optimize your results.

ACH, debit, or credit-card payments will appear on your bank statement under the name FMC.

Notify your provider immediately if you notice a lump or swelling in your neck, hoarseness, difficulty swallowing, or shortness of breath — these may be signs of thyroid cancer. Semaglutide and Tirzepatide are contraindicated if you or a family member has ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).


The safety and efficacy of combining GLP-1 medications with other weight-loss products have not been established. Always share your complete medical history with your provider, especially if you have a history of Type 1 or Type 2 diabetes, thyroid cancer, pancreatitis, kidney disease, or diabetic retinopathy.